Cerecor disappoints By: MarketMinute.com Stock News December 05, 2016 at 16:52 PM EST Cerecor Inc. (Nasdaq: CERC) reported disappointing results from Phase 2 clinical trial of CERC-501 sending the stock price down 23 cents to close at $1.52. Related Stocks: Cerecor Inc